Trial Profile
A Phase IIIB, Multicenter, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Patients With Relapsing Forms of Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary) ; Influenza A virus H1N1 vaccines; Influenza A virus vaccine-H3N2; Influenza B virus vaccine; Influenza virus vaccine; Keyhole limpet haemocyanin; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccine; Tetanus vaccine
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms VELOCE
- Sponsors Roche
- 15 Nov 2021 Status changed from active, no longer recruiting to completed.
- 13 Sep 2021 Planned End Date changed from 13 Dec 2022 to 1 Oct 2021.
- 22 Apr 2021 Results of an analysis reporting longer-term safety evaluations from following clinical trials: VELOCE, CHORDS, CASTING, OBOE, ENSEMBLE, LIBERTO and CONSONANCE published in the Neurology